Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Conditions

Ureteral Neoplasms 2Carcinoma, Transitional Cell 2Urologic Neoplasms 1Urinary Bladder Neoplasms 1Renal Pelvis and Ureter Urothelial Carcinoma 1Recurrence 1Disease 1Carcinoma 1

Interventions

Cyclophosphamide 153Dexamethasone 141Rituximab 85fludarabine 79Lenalidomide 72Cytarabine 70Bortezomib 64fludarabine phosphate 63Gemcitabine 62venetoclax 54Etoposide 53pomalidomide 52pembrolizumab 52Paclitaxel 48Cisplatin 48Carboplatin 48Peripheral Blood Stem Cell Transplantation 47Filgrastim 40Radiotherapy 39Busulfan 37Calcium Dobesilate 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 30Vincristine 29Bendamustine Hydrochloride 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Nephroureterectomy × Clear all
NCT06169436 2023-12-13

Translational Cancer Observational Protocol

IRCCS San Raffaele

Recruiting
1,250 enrolled

Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡